Literature DB >> 22413765

Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine.

Julia Staeker1, Stefan Leucht, Werner Steimer.   

Abstract

BACKGROUND AND
OBJECTIVE: Weight gain is a common problem of treatment with atypical antipsychotics. However, the dimension of body weight change differs interindividually, and various genetic factors are considered to be associated with this effect. Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala polymorphism and its reported relationship to type 2 diabetes susceptibility and body mass accumulation prompted us to investigate the impact of this single nucleotide polymorphism (SNP) on antipsychotic-induced changes of body weight and body mass index (BMI) in a naturalistic study design.
METHODS: Included were 138 olanzapine- and 32 clozapine-treated psychiatric inpatients whose demographic data, medical anamnesis, and drug treatment were assessed at admission to hospital and 4 weeks thereafter. The PPARG Pro12Ala SNP was determined with a validated real-time PCR assay.
RESULTS: In contrast to previous investigations, we did not detect significant variations of weight gain among the different PPARG Pro12Ala genotypes.
CONCLUSION: Our results suggest that the examined polymorphism appears to play a minor or no role in clinical practice concerning antipsychotic drug-induced weight gain.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22413765     DOI: 10.2165/11599880-000000000-00000

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  22 in total

1.  Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Authors:  B R Basson; B J Kinon; C C Taylor; K A Szymanski; J A Gilmore; G D Tollefson
Journal:  J Clin Psychiatry       Date:  2001-04       Impact factor: 4.384

Review 2.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

Review 3.  Olanzapine: a 5-year perspective.

Authors:  Kimberly H Littrell; Richard G Petty; Nicole M Wolf
Journal:  Expert Rev Neurother       Date:  2006-06       Impact factor: 4.618

Review 4.  Atypical antipsychotic-induced weight gain: insights into mechanisms of action.

Authors:  James L Roerig; Kristine J Steffen; James E Mitchell
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

Review 5.  The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis.

Authors:  Hebe N Gouda; Gurdeep S Sagoo; Anne-Helen Harding; Jan Yates; Manjinder S Sandhu; Julian P T Higgins
Journal:  Am J Epidemiol       Date:  2010-02-23       Impact factor: 4.897

6.  The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia.

Authors:  Hasan Herken; Mehmet Erdal; Nazan Aydin; Cem Sengul; Filiz Karadag; Omer Barlas; Fulya Akin
Journal:  DNA Cell Biol       Date:  2009-10       Impact factor: 3.311

7.  A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.

Authors:  S S Deeb; L Fajas; M Nemoto; J Pihlajamäki; L Mykkänen; J Kuusisto; M Laakso; W Fujimoto; J Auwerx
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

8.  Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.

Authors:  Richa Saxena; Benjamin F Voight; Valeriya Lyssenko; Noël P Burtt; Paul I W de Bakker; Hong Chen; Jeffrey J Roix; Sekar Kathiresan; Joel N Hirschhorn; Mark J Daly; Thomas E Hughes; Leif Groop; David Altshuler; Peter Almgren; Jose C Florez; Joanne Meyer; Kristin Ardlie; Kristina Bengtsson Boström; Bo Isomaa; Guillaume Lettre; Ulf Lindblad; Helen N Lyon; Olle Melander; Christopher Newton-Cheh; Peter Nilsson; Marju Orho-Melander; Lennart Råstam; Elizabeth K Speliotes; Marja-Riitta Taskinen; Tiinamaija Tuomi; Candace Guiducci; Anna Berglund; Joyce Carlson; Lauren Gianniny; Rachel Hackett; Liselotte Hall; Johan Holmkvist; Esa Laurila; Marketa Sjögren; Maria Sterner; Aarti Surti; Margareta Svensson; Malin Svensson; Ryan Tewhey; Brendan Blumenstiel; Melissa Parkin; Matthew Defelice; Rachel Barry; Wendy Brodeur; Jody Camarata; Nancy Chia; Mary Fava; John Gibbons; Bob Handsaker; Claire Healy; Kieu Nguyen; Casey Gates; Carrie Sougnez; Diane Gage; Marcia Nizzari; Stacey B Gabriel; Gung-Wei Chirn; Qicheng Ma; Hemang Parikh; Delwood Richardson; Darrell Ricke; Shaun Purcell
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

9.  Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells.

Authors:  Li-Hung Yang; Tzer-Ming Chen; Sung-Tsai Yu; Yen-Hui Chen
Journal:  Pharmacol Res       Date:  2007-06-19       Impact factor: 7.658

10.  Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism.

Authors:  Gavin P Reynolds; Zhi-Jun Zhang; Xiao-Bin Zhang
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

View more
  2 in total

1.  Polymorphisms of peroxisome proliferator-activated receptor γ (PPARγ) and cluster of differentiation 36 (CD36) associated with valproate-induced obesity in epileptic patients.

Authors:  Xupeng Bai; Chuncao Xu; Dingsheng Wen; Yibei Chen; Hongliang Li; Xueding Wang; Liemin Zhou; Min Huang; Jing Jin
Journal:  Psychopharmacology (Berl)       Date:  2018-07-08       Impact factor: 4.530

Review 2.  Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis.

Authors:  Jian-Ping Zhang; Todd Lencz; Ryan X Zhang; Masahiro Nitta; Lawrence Maayan; Majnu John; Delbert G Robinson; W Wolfgang Fleischhacker; Rene S Kahn; Roel A Ophoff; John M Kane; Anil K Malhotra; Christoph U Correll
Journal:  Schizophr Bull       Date:  2016-05-23       Impact factor: 9.306

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.